论文部分内容阅读
目的:分析贝伐单抗、卡培他滨联合奥沙利铂治疗晚期胃癌的效果及安全性。方法:抽取2017年1月至2019年10月德州市人民医院收治的晚期胃癌患者80例，按照抽签法将其分为两组，每组40例。观察组给予贝伐单抗、卡培他滨联合奥沙利铂治疗，常规组给予多西他赛联合顺铂、5-氟尿嘧啶治疗。比较两组治疗效果、肿瘤标志物水平及用药后不良反应。结果:观察组疾病控制率(95.00%，38/40)高于常规组(80.00%，32/40)，差异有统计学意义(χn 2＝4.114，n P＝0.043)。治疗后，观察组糖类抗原199、糖类抗原242、癌胚抗原水平低于常规组(n t＝10.073、17.186、10.886，n P＝0.002、0.001、0.001)。观察组用药后不良反应发生率(10.00%，4/40)低于常规组(27.50%，11/40)，差异有统计学意义(χn 2＝4.021，n P＝0.045)。n 结论:贝伐单抗、卡培他滨联合奥沙利铂能有效治疗晚期胃癌，患者症状改善明显，且用药后不良反应较少。“,”Objective:To analyze the efficacy and safety of bevacizumab and capecitabine combined with oxaliplatin in the treatment of patients with advanced gastric cancer.Methods:A total of 80 patients with advanced gastric cancer admitted to Dezhou People’s Hospital from January 2017 to October 2019 were divided into two groups according to the draw method, with 40 cases in each group. The observation group was treated with bevacizumab, capecitabine and oxaliplatin, and the normal group was treated with docetaxel, cisplatin and 5-fluorouracil. The treatment effects, tumor marker levels and adverse reactions after medication were compared between the two groups.Results:The disease control rate of the observation group (95.00%, 38/40) was higher than that of the normal group (80.00%, 32/40), and the difference was significant (χn 2=4.114, n P=0.043). After treatment, the levels of carbohydrate antigen 199, carbohydrate antigen 242 and carcinoembryonic antigen in the observation group were lower than those in the normal l group (n t=10.073, 17.186, 10.886, n P=0.002, 0.001, 0.001). The incidence of adverse reactions in the observation group (10.00%, 4/40) was lower than that in the normal group (27.50%, 11/40), and the difference was statistically significant (χn 2=4.021, n P=0.045).n Conclusions:Bevacizumab, capecitabine combined with oxaliplatin can effectively treat advanced gastric cancer. The symptoms of patients are improved significantly, and there are fewer adverse reactions after treatment.